Home
News
In Focus
Business
Metro
Nation
World
Sports
Feature
Opinion
View more »Opinion Columns
Wan LixinOpinion deputy editor of Shanghai Daily
Restaurants get off to a quick start thanks to game-changing policies
High service charges on event ticket refunds call for further regulation
Sunday
- Subscribe
Fosun sets eyes on becoming giant ‘Unicorn’
Print Edition
A string of overseas investments has shone a new spotlight on Chinese conglomerate Fosun.
In the space of three days last week, the Shanghai-based company bought a stake in an Indian drugmaker for US$1.26 billion, acquired a Brazilian investment firm and announced plans to take a stake in Portugal’s biggest private bank.
That came only a week after it bought English Championship football club Wolves, and two months after it was part of a consortium that signed a memorandum of understanding to buy Athens’ former main airport. Last year, it won a long-running battle to take over French holiday resorts group Club Med.
Founded 24 years ago by a group of classmates from China’s Fudan University, Fosun has announced more than US$15 billion in overseas acquisitions since 2010, according to Bloomberg News.
Started with capital of just 38,000 yuan (US$5,760), the company was an early investor in China’s pharmaceutical and steel industries, before branching out into numerous business sectors including insurance and financial services.
The Chinese government has for years encouraged companies to invest abroad to secure natural resources, open new markets and gain access to foreign technology, but the weak global economy has presented new, attractive targets.
Chinese firms’ overseas merger and acquisition deals more than doubled by value annually in the second quarter, according to law firm Baker & McKenzie, surging 132 percent to over US$40 billion.
“Lower valuations of overseas companies dragged down by the slowing economy have made them more attractive to Fosun in terms of price,” Sam Chi Yung, strategist at Delta Asia Securities in Hong Kong, said.
“Fosun has taken advantage of the circumstances to buy more overseas.”
In a two-track approach, Fosun chairman Guo Guangchang has urged proceeding slowly on future development to refine the US$60 billion company’s existing products and services, but moving fast to seize opportunities.
“When we have a very good product, we will allocate all resources to it, so that it quickly develops into a ‘Unicorn.’ Fosun eventually will become a giant ‘Unicorn’ with enormous power,” Guo said in the firm’s annual report in March.
The term unicorn typically describes technology startups valued at over US$1 billion.
Guo, often described as China’s Warren Buffett, is China’s 19th richest person in Forbes magazine’s most recent ranking, with wealth of US$5.4 billion. He cites investor Buffett, known as the Sage of Omaha, as an inspiration, along with industrial company GE and investment bank Goldman Sachs.
Hong Kong-listed Fosun reported a profit of 8.04 billion yuan in 2015, up 17.3 percent, according to its annual report.
Fosun has just announced it is acquiring Brazil-based investment management firm Rio Bravo, while its pharmaceutical arm is taking an 86 percent stake in India’s Gland Pharma, both as part of a push into developing countries.
“Our strategic deployment in Europe and the US is relatively complete. In emerging markets, it has just started,” Guo told Bloomberg News in May.
But at the same time it has accumulated billions of dollars in debt to pay for its purchases, and chief executive officer Liang Xinjun recently told Bloomberg Television that it might sell some assets to pay down the load.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
